Clinical Trial Update: A Study of PM8002 Plus Nab-paclitaxel as First Line Therapy for TNBC [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for PM8002 plus Nab-paclitaxel as first-line therapy in triple-negative breast cancer; the study is currently ACTIVE_NOT_RECRUITING.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Nab-paclitaxel (paclitaxel protein-bound)
• PM8002

Snippet

Sponsor: Biotheus Inc. | Conditions: TNBC | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING